Abstract
The increased emphasis on mechanistic and quantitative approaches in pharmacology presents new challenges to the design and analysis of mathematical models used in drug discovery. In this paper we present three of such challenges: (i) How to proceed when exposure data are scarce or plainly absent? Response versus time data for different doses are then the only source of information. (ii) The advent of biological (biologics) therapeutics has resulted in a new class of models which involve the interaction of drug and target. (iii) How to determine the impact of proteins at the target site on drug efficacy? We illustrate these challenges with three case studies.
Similar content being viewed by others
References
Aston, P.J., Derks, G., Raji, A., Agoram, B.M., van der Graaf, P.H.: Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J. Theor. Biol. 281, 113–121 (2011)
Benet, L.Z., Hoener, B.-A.: Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 116–121 (2002)
Benet, L.Z.: Clearance (née Rowland) concepts: a downdate and an update. J. Pharmacokinet. Pharmacodyn. 37, 529–539 (2010)
Dayneka, N.L., Garg, V., Jusko, W.J.: Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21, 457–478 (1993)
Gabrielsson, J., Jusko, W.J., Alari, L.: Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm. Drug Dispos. 21, 41–52 (2000)
Gabrielsson, J., Peletier, L.A.: Dose-response-time data analysis involving nonlinear dynamics, feedback and delay. Eur. J. Pharm. Sci. 59, 36–48 (2014)
Gatto, G.J., Bohme, G.A., Caldwell, W.S., Letchworth, S.R., Traina, V.M., Obinu, M.C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., Bencherif, M.: TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev. 10, 147–66 (2004)
Gibiansky, L., Gibiansky, E., Kakkar, T., Ma, P.: Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35, 573–591 (2008)
Gibiansky, L., Gibiansky, E.: Target-mediated drug disposition model: relationships with indirect response models and application to population PKPD analysis. J. Pharmacokinet. Pharmacodyn. 36, 341–351 (2009)
Levy, G.: Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J. Pharm. Sci. 53, 342–343 (1964)
Levy, G.: Kinetics of pharmacological effects. Clin. Pharmacol. Ther. 7, 362 (1966)
Luu, K.T., Bergqvist, S., Chen, E., Hu-Lowe, D., Kraynov, E.: A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J. Pharm. Exp. Ther. JPET 341, 702–708 (2012)
Mager, D.E., Jusko, W.J.: General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Phamacodyn. 28, 507–532 (2001)
Michaelis, L., Menten, M.L.: Die Kinetik der Invertinwirkung. Biochem. Z. 49, 333–369 (1913)
Ng, C.M., Joshi, A., Dedrick, R.L., Garovoy, M.R., Bauer, R.J.: Pharmacokinetic pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22, 1088–1100 (2005)
Peletier, L.A., Benson, N., van der Graaf, P.H.: Impact of plasma-protein binding on receptor occupancy: an analytical description. J. Theor. Biol. 256, 253–262 (2009)
Peletier, L.A., Benson, N., van der Graaf, P.H.: Impact of protein binding on receptor occupancy: a two-compartment model. J. Theor. Biol. 265, 657–671 (2010)
Peletier, L.A., Gabrielsson, J.: Dynamics of target-mediated drug disposition. Eur. J. Pharm. Sci. 38, 445–464 (2009)
Peletier, L.A., Gabrielsson, J.: Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J. Pharmacokinet. Pharmacodyn. 39, 429–451 (2012)
Segel, L.A., Slemrod, M.: The quasi-steady-state assumption: a case study in perturbation. SIAM Rev. 31, 446–477 (1989)
Smith, D.A., Di, L., Kerns, E.H.: The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov. 9, 929–939 (2010)
Smolen, V.F.: Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophtalmic and oral administration of a mydriatic drug. J. Pharm. Sci. 60, 354–363 (1971)
Author information
Authors and Affiliations
Corresponding author
Additional information
In honour and memory of Klaus KirchgŁassner.
Appendix A: Derivation of the expression for \(R_n(t)\) in (2.11)
Appendix A: Derivation of the expression for \(R_n(t)\) in (2.11)
Putting \(S(A_{b})=1+S_\mathrm{max}\) in the the system (2.4) we obtain the model
We shall derive an explicit solution of this problem.
For convenience we put \(R_{i} = R_{0}(1+x_{i})\) and \(\tau = k_\mathrm{out}\, t\). Then the system (5.1) can be rewritten as
This system can be solved sequentially. Since \(x_{i}(0)=0\) for \(i = 1, \dots . n\) we obtain
and for general \(n \ge 1\):
Thus, in terms of the original variables we obtain the following expression for the responses:
Rights and permissions
About this article
Cite this article
Peletier, L.A., Gabrielsson, J. Challenges in Pharmacology Modelling. J Dyn Diff Equat 27, 941–959 (2015). https://doi.org/10.1007/s10884-014-9377-y
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10884-014-9377-y